OliX PharmaceuticalsInc (KQ:226950) — Market Cap & Net Worth
Market Cap & Net Worth: OliX PharmaceuticalsInc (226950)
OliX PharmaceuticalsInc (KQ:226950) has a market capitalization of $1.49 Billion (₩2.20 Trillion) as of September 17, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #7259 globally and #183 in its home market, demonstrating a 11.08% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OliX PharmaceuticalsInc's stock price ₩108300.00 by its total outstanding shares 20300583 (20.30 Million). Also see 226950 current and non-current assets for a full breakdown of the balance sheet.
OliX PharmaceuticalsInc Market Cap History: 2020 to 2026
OliX PharmaceuticalsInc's market capitalization history from 2020 to 2026. Data shows growth from $692.00 Million to $1.49 Billion (15.34% CAGR). Also see 226950 cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
OliX PharmaceuticalsInc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$231.82 Billion | 0.64% | #31 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$231.82 Billion | 0.64% | #31 of 1384 |
Weight: OliX PharmaceuticalsInc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OliX PharmaceuticalsInc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OliX PharmaceuticalsInc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of OliX PharmaceuticalsInc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.13x
OliX PharmaceuticalsInc's market cap is 0.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $692.00 Million | $2.47 Billion | -$19.38 Billion | 0.28x | N/A |
| 2021 | $564.05 Million | $3.67 Billion | -$29.71 Billion | 0.15x | N/A |
| 2022 | $279.96 Million | $9.32 Billion | -$19.50 Billion | 0.03x | N/A |
| 2023 | $200.58 Million | $17.06 Billion | -$19.10 Billion | 0.01x | N/A |
| 2024 | $264.97 Million | $5.68 Billion | -$40.66 Billion | 0.05x | N/A |
| 2025 | $1.93 Billion | $14.67 Billion | -$15.74 Billion | 0.13x | N/A |
Competitor Companies of 226950 by Market Capitalization
Companies near OliX PharmaceuticalsInc in the global market cap rankings as of September 17, 2026. Review 226950 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to OliX PharmaceuticalsInc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
OliX PharmaceuticalsInc Historical Marketcap From 2020 to 2026
Between 2020 and today, OliX PharmaceuticalsInc's market cap moved from $692.00 Million to $ 1.49 Billion, with a yearly change of 15.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.49 Billion | -22.86% |
| 2025 | ₩1.93 Billion | +628.97% |
| 2024 | ₩264.97 Million | +32.10% |
| 2023 | ₩200.58 Million | -28.35% |
| 2022 | ₩279.96 Million | -50.37% |
| 2021 | ₩564.05 Million | -18.49% |
| 2020 | ₩692.00 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of OliX PharmaceuticalsInc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.49 Billion USD |
| MoneyControl | $1.49 Billion USD |
| MarketWatch | $1.49 Billion USD |
| marketcap.company | $1.49 Billion USD |
| Reuters | $1.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more